Wave Life Sciences (NASDAQ: WVE)
Wave Life Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Wave Life Sciences Company Info
Wave Life Sciences Ltd. is a clinical-stage genetic medicines company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, optimization, and production of novel stereopure oligonucleotides. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
News & Analysis
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
The gene-editing market is moving fast, and it pays to get to know some of these companies.
Why Wave Life Sciences Was Zooming Higher Today
The company says it has enough dosh on hand to carry it through this and next year.
Here's Why Wave Life Sciences Crashed Today
No one ever said drug development was easy.
Why Wave Life Sciences Shares Vaulted Higher Today
Investors liked an analyst's upgrade of the biotech stock.
Here's Why Shares of Wave Life Sciences Are Imploding Today
A lack of efficacy in a lead drug candidate is not what investors were expecting.
Here's Why Wave Life Sciences Is Crashing Today
Investors aren't too thrilled about this biotech's latest share offering.
Here's Why Wave Life Sciences Fell as Much as 12.1% This Morning
A new share offering was announced to raise funds for drug development activities.
Valuation
Earnings Transcripts
WAVE Life Sciences Pte. Ltd. (WVE) Q3 2020 Earnings Call Transcript
WVE earnings call for the period ending September 30, 2020.
WAVE Life Sciences Pte. Ltd. (WVE) Q2 2020 Earnings Call Transcript
WVE earnings call for the period ending June 30, 2020.
WAVE Life Sciences Pte. Ltd. (WVE) Q1 2020 Earnings Call Transcript
WVE earnings call for the period ending March 31, 2020.
WAVE Life Sciences Pte. Ltd. (WVE) Q4 2019 Earnings Call Transcript
WVE earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.